Literature DB >> 21297431

Systemic therapy for squamous cell carcinoma of the skin in organ transplant recipients.

James Leroy Wells1, Keisuke Shirai.   

Abstract

During the second half of the 20th century, organ transplantation saved thousands of lives. This, unfortunately, also led to unforeseen consequences that need to be addressed to help extend the lives of patients who require these life-saving procedures. Secondary malignancies have been recognized as a potential consequence for decades. One of these malignancies, squamous cell carcinoma of the skin, not only appears more frequently in organ transplant recipients than the general population, but also is more aggressive in organ transplant recipients. It also shows a high propensity to nodal spread and metastasis in transplant patients. Unfortunately, there are no clear guidelines for a chemotherapy in this population, who have an increased need for alternative therapies to surgery given the high recurrence and metastasis rate. In this review, we attempt to describe the characteristics of squamous cell carcinoma of the skin in transplant recipients and discuss what chemotherapeutic options can be used to treat this aggressive malignancy.

Entities:  

Mesh:

Year:  2012        PMID: 21297431     DOI: 10.1097/COC.0b013e318201a3ef

Source DB:  PubMed          Journal:  Am J Clin Oncol        ISSN: 0277-3732            Impact factor:   2.339


  11 in total

Review 1.  Management of non-melanoma skin cancer in immunocompromised solid organ transplant recipients.

Authors:  Haider K Bangash; Oscar R Colegio
Journal:  Curr Treat Options Oncol       Date:  2012-09

Review 2.  Roles of the immune system in skin cancer.

Authors:  S Rangwala; K Y Tsai
Journal:  Br J Dermatol       Date:  2011-11       Impact factor: 9.302

Review 3.  Cutaneous Squamous Cell Carcinoma in Immunosuppressed Patients.

Authors:  Samantha Tam; Neil D Gross
Journal:  Curr Oncol Rep       Date:  2019-07-29       Impact factor: 5.075

4.  MicroRNA-125b down-regulates matrix metallopeptidase 13 and inhibits cutaneous squamous cell carcinoma cell proliferation, migration, and invasion.

Authors:  Ning Xu; Lingyun Zhang; Florian Meisgen; Masako Harada; Johan Heilborn; Bernhard Homey; Dan Grandér; Mona Ståhle; Enikö Sonkoly; Andor Pivarcsi
Journal:  J Biol Chem       Date:  2012-07-10       Impact factor: 5.157

5.  Osseous metastasis of cutaneous squamous cell carcinoma treated successfully with oxaliplatin, tegafur and leucovorin combination chemotherapy: a case report.

Authors:  Hong-Wei Xu; Feng Ren; Wei Chen; Ying-Jie Wang; Jin Chen; Zhi-Hui Xie; Jin-Hu Yang; Jian-Jun Chu; Xu-Yang You
Journal:  Int J Clin Exp Med       Date:  2012-01-15

Review 6.  Unraveling cancer lineage drivers in squamous cell carcinomas.

Authors:  Yinglu Guan; Guan Wang; Danielle Fails; Priyadharsini Nagarajan; Yejing Ge
Journal:  Pharmacol Ther       Date:  2019-12-11       Impact factor: 12.310

7.  MicroRNA-135b Regulates Leucine Zipper Tumor Suppressor 1 in Cutaneous Squamous Cell Carcinoma.

Authors:  Edit B Olasz; Lauren N Seline; Ashley M Schock; Nathan E Duncan; Argelia Lopez; Jozef Lazar; Michael J Flister; Yan Lu; Pengyuan Liu; Olayemi Sokumbi; Catherine A Harwood; Charlotte M Proby; Marcy Neuburg; Zelmira Lazarova
Journal:  PLoS One       Date:  2015-05-04       Impact factor: 3.240

8.  Association of VEGF Gene Polymorphisms with the Risk and Prognosis of Cutaneous Squamous Cell Carcinoma.

Authors:  Xiao-Juan Nie; Wen-Min Liu; Li Zhang
Journal:  Med Sci Monit       Date:  2016-10-12

Review 9.  The role of miRNAs in cutaneous squamous cell carcinoma.

Authors:  Xin Yu; Zheng Li
Journal:  J Cell Mol Med       Date:  2015-10-27       Impact factor: 5.310

10.  MiR-204 silencing in intraepithelial to invasive cutaneous squamous cell carcinoma progression.

Authors:  Agustí Toll; Rocío Salgado; Blanca Espinet; Angel Díaz-Lagares; Eugenia Hernández-Ruiz; Evelyn Andrades; Juan Sandoval; Manel Esteller; Ramón M Pujol; Inmaculada Hernández-Muñoz
Journal:  Mol Cancer       Date:  2016-07-25       Impact factor: 27.401

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.